Published ahead of print on June 5, 2003, doi:10.1164/rccm.200205-447OC
Am. J. Respir. Crit. Care Med., Volume 168, Number 4, August 2003, 481-486
A more recent version of this article appeared on August 15, 2003
Submitted on May 30, 2002
Accepted on May 22, 2003
LOW DOSE VASOPRESSIN IN THE TREATMENT OF SEPTIC SHOCK IN SHEEP
Qinghua Sun1, George Dimopoulos1, Duc Nam Nguyen1, Zizhi Tu1, Nathalie Nagy1, Anh Dung Hoang1, Peter Rogiers1, Daniel De Backer1, and Jean-Louis Vincent*
1 Intensive Care, Erasme University Hospital, Brussels, Belgium
* To whom correspondence should be addressed. E-mail: jlvincen{at}ulb.ac.be.
Following induction of cecal perforation, twenty anesthetized sheep were randomized to be treated, when arterial blood pressure fell below 75 mmHg, with vasopressin (fixed dose of 0.02 U/min), norepinephrine (0.5-5 µg/kg/min titrated to maintain mean arterial pressure between 75-85 mmHg), vasopressin + norepinephrine (vasopressin at fixed dose 0.01 U/min, plus norepinephrine titrated as for norepinephrine only group), or no vasopressor (Ringer's lactate [control]). Mean arterial pressure was well maintained in all treatment groups. Superior mesenteric arterial blood flow was significantly lower in vasopressin + norepinephrine groups than in the vasopressin group. Vasopressin alone or combined with norepinephrine limited the increase in blood lactate concentration and ileal PCO2-gap compared with control and norepinephrine groups. Urine output was higher in the vasopressin group than in control and norepinephrine groups. Survival time was longer in the vasopressin (30±6h) and vasopressin + norepinephrine (30±3h) than in the norepinephrine group (20±1h, p<. 05), and in all treatment groups than in the control group (17±2 h, p<. 05). Tissue injury was less severe in the vasopressin and vasopressin + norepinephrine groups than in the others. In this clinically relevant model of septic shock due to peritonitis, vasopressin administration (alone or with norepinephrine) can prolong survival.
Key words: norepinephrine; peritonitis; sheep; survival time; histologic abnormality
This article has been cited by other articles:

|
 |

|
 |
 
F. Su, Z. Wang, Y. Cai, M. Remmelink, and J.-L. Vincent
Beneficial Effects of Ethyl Pyruvate in Septic Shock From Peritonitis
Arch Surg,
February 1, 2007;
142(2):
166 - 171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Farand, M. Hamel, F. Lauzier, G. E. Plante, and O. Lesur
Review article: Organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis: [Expose de synthese : Les effets relies a la perfusion et a la permeabilite organique de la norepinephrine et de la vasopressine durant le "sepsis"].
Can J Anesth,
September 1, 2006;
53(9):
934 - 946.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Bennett, R. P. Mahajan, J. E. March, P. A. Kemp, and S. M. Gardiner
Regional and temporal changes in cardiovascular responses to norepinephrine and vasopressin during continuous infusion of lipopolysaccharide in conscious rats
Br. J. Anaesth.,
September 1, 2004;
93(3):
400 - 407.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-L. Vincent
Evidence-Based Medicine in the ICU: Important Advances and Limitations
Chest,
August 1, 2004;
126(2):
592 - 600.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Levy, C. Vallee, F. Lauzier, G. E. Plante, A. Mansart, J.-P. Mallie, and O. Lesur
Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock
Am J Physiol Heart Circ Physiol,
July 1, 2004;
287(1):
H209 - H215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Tobin
Critical Care Medicine in AJRCCM 2003
Am. J. Respir. Crit. Care Med.,
January 15, 2004;
169(2):
239 - 253.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. De Backer, J. Creteur, J.-L. Vincent, M. W. Dunser, A. J. Mayr, H. Ulmer, H. Knotzer, G. Sumann, W. Pajk, B. Friesenecker, et al.
Arginine Vasopressin in Advanced Vasodilatory Shock * Response
Circulation,
November 11, 2003;
108
(19):
e142 - e142.
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 American Thoracic Society
|
|
|